DE69930666T2 - Krebsnachweisverfahren und reagenzien - Google Patents

Krebsnachweisverfahren und reagenzien Download PDF

Info

Publication number
DE69930666T2
DE69930666T2 DE69930666T DE69930666T DE69930666T2 DE 69930666 T2 DE69930666 T2 DE 69930666T2 DE 69930666 T DE69930666 T DE 69930666T DE 69930666 T DE69930666 T DE 69930666T DE 69930666 T2 DE69930666 T2 DE 69930666T2
Authority
DE
Germany
Prior art keywords
cancer
autoantibodies
marker protein
protein
muc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930666T
Other languages
German (de)
English (en)
Other versions
DE69930666D1 (de
Inventor
Russell John Attenborough ROBERTSON
Rosamund Catherine Kinoulton GRAVES
Frances PRICE (Legal representative of PRI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Freenome Ltd
Original Assignee
University of Nottingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nottingham filed Critical University of Nottingham
Application granted granted Critical
Publication of DE69930666D1 publication Critical patent/DE69930666D1/de
Publication of DE69930666T2 publication Critical patent/DE69930666T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69930666T 1998-12-10 1999-12-10 Krebsnachweisverfahren und reagenzien Expired - Lifetime DE69930666T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9827228 1998-12-10
GBGB9827228.9A GB9827228D0 (en) 1998-12-10 1998-12-10 Cancer detection method and reagents
PCT/GB1999/004182 WO2000034787A1 (en) 1998-12-10 1999-12-10 Cancer detection method and reagents

Publications (2)

Publication Number Publication Date
DE69930666D1 DE69930666D1 (de) 2006-05-18
DE69930666T2 true DE69930666T2 (de) 2007-01-11

Family

ID=10844007

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930666T Expired - Lifetime DE69930666T2 (de) 1998-12-10 1999-12-10 Krebsnachweisverfahren und reagenzien

Country Status (13)

Country Link
US (2) US7205117B1 (https=)
EP (1) EP1137943B1 (https=)
JP (1) JP4665069B2 (https=)
AT (1) ATE322014T1 (https=)
AU (1) AU1671300A (https=)
CA (1) CA2354702C (https=)
CY (1) CY1105697T1 (https=)
DE (1) DE69930666T2 (https=)
DK (1) DK1137943T3 (https=)
ES (1) ES2257087T3 (https=)
GB (1) GB9827228D0 (https=)
PT (1) PT1137943E (https=)
WO (1) WO2000034787A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
GB2424273B (en) 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
US20040137538A1 (en) * 2003-01-10 2004-07-15 Bradford Sherry A. Cancer comprehensive assay kit for identifying cancer protein patterns
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
CA2595778A1 (en) * 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. Anti-muc1 .alpha..beta. antibodies
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
CN103245784A (zh) * 2005-11-10 2013-08-14 肯塔基大学研究基金会 肺癌的诊断分析法
KR20090034961A (ko) * 2006-07-08 2009-04-08 유니버시티 오브 켄터키 리서치 파운데이션 폐암 진단 검사
US8574848B2 (en) 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
US9111950B2 (en) * 2006-09-28 2015-08-18 Philips Lumileds Lighting Company, Llc Process for preparing a semiconductor structure for mounting
CA2670471A1 (en) 2006-11-22 2008-06-05 Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
US20120003225A1 (en) * 2008-05-09 2012-01-05 Duke University Autoantibodies in the detection and treatment of cancer
PE20091931A1 (es) 2008-05-22 2009-12-31 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
US8852870B2 (en) 2008-06-16 2014-10-07 University Of Louisville Research Foundation, Inc. Systems and methods for diagnosis and prognosis of cancer
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20110237461A1 (en) 2010-03-17 2011-09-29 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
WO2011120015A2 (en) * 2010-03-26 2011-09-29 Armune Biosciences, Inc. Method and system of particle-coupled phage epitope
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
CN102680456B (zh) * 2011-03-16 2015-07-08 北京联众泰克科技有限公司 一种电化学发光免疫测定方法
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US20130040839A1 (en) * 2011-06-27 2013-02-14 Ambergen, Inc. Method for Diagnosing or Determining the Prognosis of Colorectal Cancer (CRC) Using Novel Autoantigens: Gene Expression Guided Autoantigen Discovery
EP2756307B1 (en) 2011-09-15 2020-10-21 Vaxil Bio Therapeutics Ltd. Antibodies directed against signal peptides, methods and uses thereof
EP3129401B1 (en) 2014-03-20 2019-06-12 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type iii domains
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
CN109116024B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-actr3自身抗体及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241044A (en) * 1978-12-28 1980-12-23 Abbott Laboratories Method of diagnosing cancer by detecting elevated anti-T antibody activity
US4562160A (en) * 1983-04-01 1985-12-31 Sloan-Kettering Institute Melanoma tumor antigen and autologous antibody
US5106738A (en) * 1984-01-31 1992-04-21 Akzo Nv Tumor specific monoclonal antibodies
NZ211453A (en) 1984-03-22 1989-01-06 Biotechnology Research Enterpr Aryl azides, their preparation and use in the detection, localisation and isolation of polynucleotides
DE3685818T2 (de) 1986-03-10 1993-01-14 Imre Corp Immunkomplextestverfahren.
US4937185A (en) 1987-07-31 1990-06-26 The Ohio State University Research Foundation Detection of circulating antibodies to a cancer marker protein
US7282345B1 (en) * 1989-08-04 2007-10-16 Schering Ag C-erbB-2 external domain: GP75
US5110911A (en) * 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5157020A (en) * 1990-05-24 1992-10-20 Research Corporation Tech., Inc. Synthetic senescent cell antigen
DK9091D0 (da) * 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
DE4120412C1 (https=) * 1991-06-20 1993-01-07 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
US6322989B1 (en) 1991-11-25 2001-11-27 Yoreh Biotechnologies, Ltd. Whole blood/mitogen assay for the early detection of a subject with ovarian or breast cancer and kit
US6280962B1 (en) * 1991-11-25 2001-08-28 Yoreh Biotechnologies Ltd. Whole blood/mitogen assay for the early detection of a subject with cancer and kit
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
EP0636248A4 (en) 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5763164A (en) 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US5747268A (en) * 1993-04-22 1998-05-05 Dade International Inc. Tumor marker control
IT1270939B (it) * 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5721105A (en) * 1994-02-20 1998-02-24 B.R.A.H.M.S. Diagnostica Gmbh Method for the immunological determination of proteins and kit for carrying out the method
WO1996000084A1 (en) * 1994-06-24 1996-01-04 Torchilin Vladimir P Use of autoantibodies for tumor therapy and prophylaxis
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US5561049A (en) * 1994-09-21 1996-10-01 Behringwerke Ag Method for detecting antibodies
US5876728A (en) 1995-02-15 1999-03-02 Howard David Kass Natural composition extracted from plants used in the treatment of cancer
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
JPH09189702A (ja) 1996-01-09 1997-07-22 Hitachi Chem Co Ltd 抗ムチン抗体の測定法、癌の測定法及び癌診断薬
JP2001517206A (ja) * 1996-08-16 2001-10-02 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法
DE19805815C1 (de) * 1998-02-13 1999-11-11 Ansgar W Lohse Diagnostikum zum Erkennen der autoimmunen Hepatitis
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
DE69941627D1 (de) 1998-11-05 2009-12-17 Univ Michigan Für krebs
US6387639B1 (en) * 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
US7807810B2 (en) * 1999-04-08 2010-10-05 The Ohio State University Research Foundation Nucleic acids encoding the major outer membrane protein of the causative agent of human granulocytic ehrlichiosis and peptides encoded thereby
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020064801A1 (en) * 1999-12-01 2002-05-30 Ryan Jeffrey R. Novel and practical serological assay for the clinical diagnosis of leishmaniasis
US6667160B2 (en) * 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US20030138860A1 (en) * 2000-06-14 2003-07-24 Robertson John Forsyth Russell Cancer detection methods and reagents
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
CA2451045A1 (en) * 2001-06-21 2003-09-04 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
US20030049692A1 (en) * 2002-09-16 2003-03-13 Norman Latov Detection of anti-glycolipid antibodies by latex agglutination assay
GB2424273B (en) * 2002-11-14 2007-06-27 Univ Nottingham Method for preparing tumour marker protein
JP2005352771A (ja) * 2004-06-10 2005-12-22 Hitachi Software Eng Co Ltd 発現プロファイルによるパターン認識システム
US20060141547A1 (en) * 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
WO2007032634A1 (en) * 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University A method for production of mature natural killer cell
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay

Also Published As

Publication number Publication date
ES2257087T3 (es) 2006-07-16
JP2002532686A (ja) 2002-10-02
PT1137943E (pt) 2006-08-31
US7205117B1 (en) 2007-04-17
ATE322014T1 (de) 2006-04-15
CY1105697T1 (el) 2010-12-22
US20080108084A1 (en) 2008-05-08
AU1671300A (en) 2000-06-26
WO2000034787A1 (en) 2000-06-15
EP1137943A1 (en) 2001-10-04
DK1137943T3 (da) 2006-07-31
JP4665069B2 (ja) 2011-04-06
GB9827228D0 (en) 1999-02-03
CA2354702A1 (en) 2000-06-15
EP1137943B1 (en) 2006-03-29
CA2354702C (en) 2013-03-26
DE69930666D1 (de) 2006-05-18

Similar Documents

Publication Publication Date Title
DE69930666T2 (de) Krebsnachweisverfahren und reagenzien
DE69929185T2 (de) Tumormarker
DE69837529T2 (de) Proteinmarker für lungenkrebs und deren verwendung
DE69028513T2 (de) Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
DD202178A5 (de) Verfahren und reagens zur untersuchung von antigen-antikoerper-reaktionen
DE69127487T2 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
EP0008432A1 (de) Immunologisches Bestimmungsverfahren
DE60034480T2 (de) Diagnostischer assay für schlaganfall
EP0460190B1 (de) Verfahren zum nachweis von malignen erkrankungen
DE60114823T2 (de) Inter-alpha-trypsin als marker für sepsis
DE69204718T2 (de) CA-195 ähnliches immunreaktives Antigen von menschlicher Amnionflüssigkeit.
Kelly et al. Qualitative testing for circulating immune complexes by use of zone electrophoresis on agarose.
DE19920704C1 (de) Verwendung eines gegen Harn-Trypsin-Inhibitors gerichteten Antikörpers für die Diagnose des Ausbruchs von AIDS
EP0974841A2 (de) Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
EP0829723B1 (de) Homogene Nachweisverfahren zur Bestimmung von Subpopulationen eines Analyten
DE69822149T2 (de) Erkennung von tmorspezifische genprodukte
DE69621837T2 (de) Methoden zur feststellung von alzheimerscher krankheit
DE69733957T2 (de) Verfahren zur bestimmung der gegenwart des gehirnspezifischen proteins s-100 beta
EP0267355B1 (de) Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine
DE69322847T2 (de) Monoklonaler Antikörper gegen menschliches Ceruloplasmin
DE69128238T2 (de) Nachweis von thrombopenies
DE68926245T2 (de) Nachweis der basismembrankomponenten, diagnose von krebs und sonstigen krankheiten
EP0267356B1 (de) Verfahren und Testelement zum Auffinden von Zelläsionen
DE69426383T2 (de) Verfahren zur Bestimmung vom rheumatoiden Faktor und Kit dazu
DE69127255T2 (de) Verfahren zur Messung von menschlichem C-Peptid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ONCIMMUNE LTD., NOTTINGHAM, GB

8327 Change in the person/name/address of the patent owner

Owner name: ONCIMMUNE LIMITED, NOTTINGHAM, GB